One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to address that disease,” Colin Murdoch, Isomorphic Labs president and Google ...

A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But can we trust drugs designed by a mind that isn't human?

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is ...

Isomorphic Labs is a London-based drug developer that’s owned and operated by Alphabet Inc. The company was founded in 2021 as an offshoot from DeepMind, Google’s multidisciplinary AI research ...

AlphaFold was developed by John Jumper and Demis Hassabis, who won the Nobel Prize in 2024. Isomorphic Labs has been working on other AI models to help design new therapies.

Isomorphic Labs is advancing a broad and ambitious drug design portfolio through partnered programs and wholly-owned internal programs. For more information, go to and follow us on LinkedIn and X .

The reasons why are beyond the scope of this article (and will no doubt be engaged with by Isomorphic Labs in the near future) but it is clear these AI systems are not miracle factories, just ...

Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 Million in its first external funding round. The financing round is led by Thrive Capital, with ...

Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. LONDON ...